Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials.
Tanizawa Y, Kaku K, Araki E, Tobe K, Terauchi Y, Utsunomiya K, Iwamoto Y, Watada H, Ohtsuka W, Watanabe D, Suganami H; Tofogliflozin 004 and 005 Study group. Tanizawa Y, et al. Among authors: suganami h. Expert Opin Pharmacother. 2014 Apr;15(6):749-66. doi: 10.1517/14656566.2014.887680. Epub 2014 Feb 11. Expert Opin Pharmacother. 2014. PMID: 24512053 Clinical Trial.
Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study.
Kaku K, Watada H, Iwamoto Y, Utsunomiya K, Terauchi Y, Tobe K, Tanizawa Y, Araki E, Ueda M, Suganami H, Watanabe D; Tofogliflozin 003 Study Group. Kaku K, et al. Among authors: suganami h. Cardiovasc Diabetol. 2014 Mar 28;13:65. doi: 10.1186/1475-2840-13-65. Cardiovasc Diabetol. 2014. PMID: 24678906 Free PMC article. Clinical Trial.
Predictors of the response of HbA1c and body weight after SGLT2 inhibition.
Abe T, Matsubayashi Y, Yoshida A, Suganami H, Nojima T, Osawa T, Ishizawa M, Yamamoto M, Fujihara K, Tanaka S, Kaku K, Sone H. Abe T, et al. Among authors: suganami h. Diabetes Metab. 2018 Mar;44(2):172-174. doi: 10.1016/j.diabet.2017.10.003. Epub 2017 Nov 8. Diabetes Metab. 2018. PMID: 29128289 Clinical Trial. No abstract available.
Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin.
Ouchi M, Oba K, Kaku K, Suganami H, Yoshida A, Fukunaka Y, Jutabha P, Morita A, Otani N, Hayashi K, Fujita T, Suzuki T, Yasutake M, Anzai N. Ouchi M, et al. Among authors: suganami h. Diabetes Obes Metab. 2018 Apr;20(4):1061-1065. doi: 10.1111/dom.13170. Epub 2018 Jan 8. Diabetes Obes Metab. 2018. PMID: 29171930 Free PMC article.
This is in reply to the Letter by Kahathuduwa et al. titled "Unaccounted for regression to the mean renders conclusion of article titled 'Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor Tofogliflozin' unsubstantiated".
Ouchi M, Oba K, Suganami H, Yoshida A, Fujita T, Suzuki T, Yasutake M, Kaku K. Ouchi M, et al. Among authors: suganami h. Diabetes Obes Metab. 2018 Aug;20(8):2041-2042. doi: 10.1111/dom.13347. Epub 2018 Jun 5. Diabetes Obes Metab. 2018. PMID: 29749099 No abstract available.
63 results